Innovation1 Biotech Inc. (IVBT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -5.68 Million USD | 54.84% |
| 2022 | -38.32 Million USD | -1448.85% |
| 2021 | -257.02 Thousand USD | 82.53% |
| 2020 | -1.28 Million USD | -44.45% |
| 2019 | -167.56 Thousand USD | 37.98% |
| 2018 | -973.47 Thousand USD | -2995.12% |
| 2017 | - USD | -2.41% |
| 2016 | - USD | -141.05% |
| 2015 | -14.52 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - USD | 54.84% |
| 2023 Q2 | -203.35 Thousand USD | 20.57% |
| 2023 Q3 | -203.35 Thousand USD | 0.0% |
| 2023 Q4 | -1.23 Million USD | -508.92% |
| 2023 Q1 | -256.01 Thousand USD | 55.62% |
| 2022 Q1 | -361.07 Thousand USD | -374.74% |
| 2022 FY | - USD | -1448.85% |
| 2022 Q4 | -576.9 Thousand USD | 16.97% |
| 2022 Q3 | -694.85 Thousand USD | 21.55% |
| 2022 Q2 | -885.67 Thousand USD | -145.29% |
| 2021 FY | - USD | 82.53% |
| 2021 Q3 | -37.88 Thousand USD | -15.57% |
| 2021 Q2 | -32.78 Thousand USD | -21.72% |
| 2021 Q1 | -26.93 Thousand USD | -112.35% |
| 2021 Q4 | -76.05 Thousand USD | -100.75% |
| 2020 Q3 | -571.93 Thousand USD | -6.44% |
| 2020 Q2 | -537.31 Thousand USD | -421.38% |
| 2020 Q4 | 218.15 Thousand USD | 138.14% |
| 2020 Q1 | -103.05 Thousand USD | 48.48% |
| 2020 FY | - USD | -44.45% |
| 2019 Q3 | -142.9 Thousand USD | 7.16% |
| 2019 Q2 | -153.93 Thousand USD | 19.55% |
| 2019 Q1 | -191.34 Thousand USD | 76.39% |
| 2019 FY | - USD | 37.98% |
| 2019 Q4 | -200.05 Thousand USD | -39.99% |
| 2018 Q4 | -810.51 Thousand USD | -4248.04% |
| 2018 Q2 | -121.77 Thousand USD | -437.35% |
| 2018 Q1 | -22.66 Thousand USD | -49.43% |
| 2018 FY | - USD | -2995.12% |
| 2018 Q3 | -18.64 Thousand USD | 84.69% |
| 2017 Q3 | -3975.00 USD | 15.44% |
| 2017 Q4 | -15.16 Thousand USD | -281.53% |
| 2017 FY | - USD | -2.41% |
| 2017 Q1 | -12 Thousand USD | -71.54% |
| 2017 Q2 | -4701.00 USD | 60.85% |
| 2016 Q1 | -7844.00 USD | -169.37% |
| 2016 Q4 | -7000.00 USD | 53.33% |
| 2016 Q3 | -15 Thousand USD | -190.47% |
| 2016 Q2 | -5164.00 USD | 34.17% |
| 2016 FY | - USD | -141.05% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | -2034.00 USD | 0.0% |
| 2015 Q3 | -3820.00 USD | -87.81% |
| 2015 Q4 | -2912.00 USD | 23.77% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -1170.702% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 80.737% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 95.017% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 63.938% |
| Better Therapeutics, Inc. | -38.26 Million USD | 85.145% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 85.146% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 68.223% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 83.151% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 82.969% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 94.655% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -522.213% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 82.502% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 87.827% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 65.133% |
| Molecular Templates, Inc. | 1.43 Million USD | 497.465% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 59.036% |
| NexImmune, Inc. | -28.16 Million USD | 79.822% |
| Orgenesis Inc. | -60.71 Million USD | 90.639% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 88.919% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -7641.837% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 64.796% |
| Scopus BioPharma Inc. | -11.71 Million USD | 51.475% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 98.947% |
| Statera Biopharma, Inc. | 38.93 Million USD | 114.598% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 17.435% |
| Trevena, Inc. | -35.28 Million USD | 83.893% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -10040.313% |
| Vaccinex, Inc. | -19.74 Million USD | 71.219% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -442.872% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 87.871% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 21.744% |